Monte Rosa Therapeutics (GLUE) Profit After Tax (2020 - 2026)

Monte Rosa Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$44.5 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 194.91% year-over-year to -$44.5 million; the TTM figure through Mar 2026 stood at -$130.0 million (down 2212.55% YoY), while the FY2025 annual figure was -$38.6 million, up 46.91% from the prior year.
• Profit After Tax was -$44.5 million for Q1 2026 at Monte Rosa Therapeutics, up from -$46.1 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $46.9 million in Q1 2025 to a low of -$46.1 million in Q4 2025.
• Historically, Profit After Tax has averaged -$23.5 million across 5 years, with a median of -$30.3 million in 2024.
• Biggest YoY gain for Profit After Tax was 246.66% in 2025; the steepest drop was 443.15% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$30.8 million in 2022, then slipped by 8.11% to -$33.3 million in 2023, then soared by 140.35% to $13.4 million in 2024, then tumbled by 443.15% to -$46.1 million in 2025, then gained by 3.49% to -$44.5 million in 2026.
• The last three Profit After Tax figures came in at -$44.5 million (Q1 2026), -$46.1 million (Q4 2025), and -$27.1 million (Q3 2025), per Business Quant data.